Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 [Yahoo! Finance]
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025